BMO Capital Believes Cooper Co (COO) Still Has Room to Grow


BMO Capital analyst Joanne Wuensch maintained a Buy rating on Cooper Co (NYSE: COO) today and set a price target of $285. The company’s shares closed yesterday at $263.69, close to its 52-week high of $266.99.

According to TipRanks.com, Wuensch is a 5-star analyst with an average return of 14.6% and a 73.5% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Baxter International, and Edwards Lifesciences.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cooper Co with a $280.67 average price target, which is a 6.4% upside from current levels. In a report released today, Piper Jaffray also maintained a Buy rating on the stock with a $280 price target.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $266.99 and a one-year low of $216.47. Currently, Cooper Co has an average volume of 392.4K.

Based on the recent corporate insider activity of 42 insiders, corporate insider sentiment is negative on the stock. Last month, Stanley Zinberg, a Director at COO sold 6,500 shares for a total of $1,550,055.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

The Cooper Cos, Inc. operates as a medical device company. It operates through the following business units: Cooper Vision and Cooper Surgical. The Cooper Vision business unit brings a refreshing perspective on vision care with a commitment to crafting quality lenses for contact lens wearers.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts